BIO Notebook: MFN, Potential China Deals Ban Weigh Heavily On Dealmaking
The BIO annual meeting continues with pharma execs reacting to potential legislation blocking deals with China, a look at how most favored nation pricing policies are affecting deal terms, NVIDIA's new agentic AI toolkit for life sciences, and FDA officials discuss hiring efforts.
Scrip - June 24, 2026

Abiomed’s Impella Safety Actions Mount As FDA Flags Another Class I Controller Correction
The latest FDA Class I correction for Abiomed’s Automated Impella Controllers is over a software error that can stop the heart pump for up to 75 seconds — the newest in a run of safety actions on J&J's Impella franchise, with deaths and injuries reported.
Medtech Insight - June 23, 2026

India Considers Letting Hospitals Bypass Import Rules For High-End Medical Equipment, Faces Pushback
India's drug regulator has proposed letting hospitals import high-end medical equipment directly — bypassing the licensing framework every other importer must follow. Domestic manufacturers say it contradicts Make in India, creates safety gaps, and favors foreign OEMs over local industry.
Medtech Insight - June 23, 2026

UK MHRA’s Global Device Ambitions Extend To Two-Way Reliance
Rob Reid, the MHRA’s deputy director for innovative devices, gave a snapshot of the agency’s current device regulatory agenda to Medtech Insight.
Medtech Insight - June 23, 2026

Doctors Rank ChatGPT Health Answers Higher Than Physician Responses, OpenAI Claims
Physicians have reviewed 700,000 AI responses to optimize health answers for GPT-5.5 Instant, OpenAI said.
Medtech Insight - June 23, 2026

Peptides Part Of Diet ‘Our Whole Life’ But Do They Qualify As Dietary Ingredients Under DSHEA?
Pharmaceutical firms protecting investments in GLP-1s and regulators considering whether supplements containing peptides are unapproved drugs should know that peptides are ingredient options under DSHEA as well as staples of ordinary diets for centuries.
HBW Insight - June 24, 2026

Supplement Firms Begin To Expect Enforcement Against Peptide Ingredients ‘Around The Corner’
Supplement marketers “really feel like we're going to open the paper or turn on the radio one day and find out our products are non-compliant,” says Jeff Cohen, co-founder of the American Peptide Association.
HBW Insight - June 24, 2026

Givaudan Launches Slow-Release Scent Technology For Hair
Swiss fragrance and flavors company Givaudan launches Aquamelon, an extended-release fragrance molecule for hair care products.
HBW Insight - June 24, 2026

First Patients Treated With Beximco’s Generic Version Of Trikafta
At $12,750 per year versus $370,000 for Trikafta, Beximco's generic is now in patients' hands, with orders placed from June scheduled for November distribution via a single authorized global supplier.
Generics Bulletin - June 23, 2026

Henlius And Organon Deepen Canada’s Denosumab Biosimilar Race
Henlius and Organon have launched Bildyos and Tuzemty in Canada, adding two more denosumab biosimilars to an increasingly crowded market while expanding Organon’s bone-care and oncology biosimilars portfolio.
Generics Bulletin - June 23, 2026

Adalvo Adds HIV Asset To Expanding Day-One Pipeline
Adalvo’s European DCP filing for generic dolutegravir adds an HIV asset to a growing slate of complex generics, value-added medicines and day-one launch programs spanning antivirals, oncology, dermatology and rare diseases.
Generics Bulletin - June 23, 2026

J&J Widens Golimumab Patent Fight With Alvotech Lawsuit
Janssen’s latest suit adds Alvotech to the US golimumab patent fight, threatening AVT05’s planned December approval as biosimilar competition builds around the $1.1bn Simponi franchise.
Generics Bulletin - June 23, 2026

After The Genome, The Epiproteome
Rising Leader Yifat Merbl has been mapping the epiproteome — biology's hidden post-translational layer — and co-founded Promise Bio to predict which autoimmune patients will respond to which drugs.
In Vivo - June 23, 2026

AI Center Stage For Biomed Israel Start-Up Winners 2026
Four innovators, Protai, BAIBYS, caVos Biotherapeutics and Starget Pharma, won Biomed Israel’s 2026 start-up showcase competition.
In Vivo - June 23, 2026

Pharma World Preview 2026: The Formula And Its Fractures
Pharma is generating bigger returns from smaller bets. Evaluate’s World Preview 2026 shows an industry that has found its formula — and is squeezing it hard. The question is how long it holds.
In Vivo - June 23, 2026